New hope for SCA patients: expanded access to investigational drug troriluzole
NCT ID NCT06034886
First seen Jan 11, 2026 · Last updated May 15, 2026 · Updated 23 times
Summary
This program offers the investigational drug troriluzole to people with spinocerebellar ataxia (SCA) who are not eligible for other trials. SCA is a rare, progressive disease that affects coordination and balance. The goal is to provide access to a potential treatment that may help control symptoms, but it is not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPINOCEREBELLAR ATAXIAS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.